文献速递生殖医学

不同卵母细胞发育能力模型的蛋白质组特征

A proteomic signature of oocyte quality from models of varying oocyte developmental competence.
PubMed 文献 · Hum Reprod · 2026-01-01

该基础研究用小鼠模型比较体内成熟、CAPA-IVM和标准IVM三种卵母细胞成熟方式的蛋白质组,并在人GV和MII卵母细胞中验证关键蛋白。发现体外成熟卵母细胞真核翻译、自噬和内吞通路失调, cumulus细胞ROS解毒和丝氨酸合成改变,提示这些过程是卵母细胞质量的重要组分且在当前IVM系统中不理想。

要点

  • 体外成熟卵母细胞真核翻译、自噬和内吞通路失调。
  • cumulus细胞ROS解毒和丝氨酸合成在IVM中改变。
  • 关键蛋白变化在人GV和MII卵母细胞中保守。

核心结论

  • 体外成熟卵母细胞在真核翻译、自噬和内吞通路上失调,cumulus细胞ROS解毒和丝氨酸合成改变,这些过程构成卵母细胞质量的重要组分且在当前IVM系统中不理想。

研究设计与样本

  • 基础研究,使用4-6周龄C57BL/6JAusb小鼠,比较体内成熟、CAPA-IVM和标准IVM三种卵母细胞成熟模型。
  • 小鼠蛋白质组实验4个生物学重复,免疫细胞化学实验3个生物学重复,胚胎学实验6个重复。
  • 人卵母细胞来自36名患者ART周期共49个卵母细胞,部分行rescue-IVM,用于免疫荧光验证。

主要发现

  • 在小鼠卵母细胞中鉴定约1600种蛋白,cumulus细胞中约3100种蛋白。
  • 体内与体外成熟系统间持续差异表达蛋白的阈值为log2FC ±1且P值≤0.05。
  • clathrin、核糖体蛋白L24和真核起始因子2A的表达在人GV和MII卵母细胞中保守。
  • 小鼠cumulus细胞中ferredoxin-1和phosphoglycerate dehydrogenase荧光强度变化支持IVM中cumulus细胞过程失调。

关键数值与推荐

  • 差异表达分析采用log2FC ±1且P值≤0.05作为阈值。
  • 蛋白质组学鉴定要求每个蛋白至少两个肽段。

临床怎么用

  • 当前IVM系统在蛋白储存与降解及cumulus细胞代谢方面可能欠佳,优化IVM方案时可考虑这些蛋白通路。
  • 关键蛋白变化在人卵母细胞中保守,提示可作为评估卵母细胞质量的候选标志物方向。

局限性

  • 卵母细胞发育能力的 foundational 机制仍不清楚,尤其人类同一刺激周期和患者间MII卵母细胞质量异质。
  • 研究受限于低表达蛋白的检测和蛋白质组覆盖度。
  • 无法在人CAPA-IVM和IVM卵母细胞中检查分子保守性。
  • 小鼠体外系统使用fetuin,且卵母细胞样本可能存在角蛋白污染来源。
  • 使用C57Bl6/J小鼠模型,将小鼠发现外推至人卵母细胞质量调控机制需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Which proteins underpin oocyte developmental competence, as modelled by oocytes of variable competence matured in vivo or matured in vitro under different conditions (capacitation in vitro maturation (CAPA-IVM) or standard IVM)? SUMMARY ANSWER: Significant differences in the global proteome were observed in both oocytes and their corresponding cumulus cells depending on the mode of oocyte maturation, with key variations in eukaryotic translation, autophagy, and endocytosis pathways within oocytes, and changes in reactive oxygen species detoxification and serine biosynthesis in cumulus cells. WHAT IS KNOWN ALREADY: Within the ovarian follicle, mammalian oocytes must acquire the necessary molecular machinery to support successful fertilization and embryonic development. Close contact with the surrounding cumulus cells ensures coordinated nuclear and cytoplasmic maturation of the oocyte, along with the accumulation of proteins stored within the oocyte in cytoplasmic lattices and endo-lysosomal vesicular assemblies. STUDY DESIGN, SIZE, DURATION: This basic science study utilized a mouse model to assess proteomic changes across three oocyte competence models. Key proteins identified in mouse oocytes were also assessed in discarded immature human germinal vesicle (GV) oocytes and MII oocytes following rescue-IVM. Three oocyte maturation methods were tested: (i) in vivo maturation, (ii) CAPA-IVM, and (iii) standard IVM. In vivo maturation served as a positive control group, whereby metaphase II (MII) mature oocytes were collected from mice stimulated with pregnant mare serum gonadotropin (PMSG) and triggered with hCG, simulating full ovarian stimulation. For the IVM groups, immature cumulus-oocyte complexes (COCs) were collected from mildly stimulated (23 h PMSG) mice. For the standard IVM group, immature COCs were matured in media containing amphiregulin and epiregulin for 18 h. For the CAPA group, COCs were held for 24 h in pre-IVM conditions in the presence of c-type natriuretic peptide (CNP), oestradiol, insulin, and FSH, and then matured via IVM in media containing FSH, amphiregulin, and epiregulin. Four biological replicates were performed for mouse proteomics experiments; three biological replicates were performed for mouse immunocytochemistry experiments; and six replicates were performed for embryology experiments. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Four- to six-week-old C57BL/6JAusb mice were used for all mouse experiments. Embryology outcomes were used to confirm the variation in oocyte developmental competence between the three maturation groups. For the in vivo, CAPA and IVM groups, mature MII COCs were collected and separated into oocytes and cumulus cells. Oocytes and cumulus cells were subjected to mass spectrometry and bioinformatic analysis was performed using Proteome Discoverer and Ingenuity Pathway Analysis, with data validated by immunofluorescence. To assess conservation of proteins in human oocytes, 49 oocytes were collected from 36 patients following ART cycles and subject to immunofluorescence. Rescue-IVM was also performed with half of the human oocyte cohort to obtain MII oocytes. MAIN RESULTS AND THE ROLE OF CHANCE: Proteomic profiling (at least two peptides per protein) identified around 1600 proteins in mouse oocytes and 3100 proteins in mouse cumulus cells across all three treatment groups. Differential expression analysis and pattern analysis collectively revealed a signature of proteins that were consistently differentially expressed between in vivo and in vitro oocyte maturation systems (log2FC of ± 1 and a P-value ≤ 0.05). These subsets of proteins were mapped to biological processes including eukaryotic translation, autophagy, and endocytosis pathways within oocytes. Orthogonal validation of clathrin, ribosomal protein L24, and eukaryotic initiation factor 2A supported the proteomic findings, and their expression was conserved in human GV and MII oocytes. Changes in reactive oxygen species detoxification and serine biosynthesis were observed in mouse cumulus cells, with fluorescence intensity changes in ferredoxin-1 and phosphoglycerate dehydrogenase supporting the dysregulation of cumulus cell processes during IVM. LARGE SCALE DATA: The mass spectrometry data are available via ProteomeXchange with identifier PXD073269. LIMITATIONS, REASONS FOR CAUTION: The foundational mechanisms of oocyte developmental competence remain elusive, particularly in humans where MII oocytes are heterogenous in quality within the same stimulation cycle and patient. Limitations in this study include the detection and proteome coverage of poorly expressed proteins, the inability to check molecular conservation in human CAPA-IVM and IVM oocytes, the use of fetuin in the mouse in vitro systems, and the potential source of keratin proteins in oocyte samples, and these factors must all be carefully considered. C57Bl6/J mice were used as the model species, allowing precise control over differing models of oocyte quality and capacity to analyse large numbers of oocytes. However, care is required when interpreting the significance of these findings in mice to mechanisms regulating human oocyte quality. Nonetheless, the in vivo stimulation and both IVM protocols used in this study are clinically relevant and developmentally matched. This study has also not addressed oocyte developmental competence in gonadotropin-free IVM oocytes, which is now a clinical reality. WIDER IMPLICATIONS OF THE FINDINGS: This study adds to the wider literature indicating that oocytes matured in vitro, either through CAPA-IVM or IVM, are unable to achieve the developmental competence rates observed with in vivo stimulation. Through examination of the global proteome in oocytes, molecular pathways including eukaryotic translation, autophagy, and endocytosis were dysregulated in in vitro oocytes. Recent findings have revealed the critical role of these pathways to developmental competence in the context of in vivo development. In cumulus cells, changes in reactive oxygen species detoxification and serine biosynthesis were observed, adding to the extensive knowledge around metabolic activity in cumulus cells as a critical facet of oocyte quality. Combined, these data suggest that the necessary processes of protein storage and degradation in oocytes and metabolism in cumulus cells constitute important components of oocyte quality. These processes appear suboptimal in current IVM systems, providing a future research direction to optimize IVM protocols with consideration to these protein pathways. FUNDING: This study was funded by a National Health and Medical Research Council Investigator Fellowship (APP1023210) awarded to R.B.G. and by a gift from Open Philanthropy. DISCLOSURES: R.B.G. is a consultant to Dioseve Inc. L.E.W. is a co-founder, shareholder, director, and advisor of Jumpstart Fertility Inc. L.E.W. is also an advisor and shareholder in EdenRoc Sciences, the parent company of Metro Biotech NSW and Metro Biotech, and in Life Biosciences LLC and its daughter companies. His UNSW Industry Scientia position is partly funded by Proto Axiom. All other authors have no competing interests to disclose.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Frost ER, Richani D, Poljak A, et al. A proteomic signature of oocyte quality from models of varying oocyte developmental competence. Hum Reprod. 2026. PMID: 42625370. doi:10.1093/humrep/deag134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。